Returning in May 2019
Boston, MA

 

2018 Speakers

Expand/Collapse

Paul Hockings
Head of Imaging
Antaros Medical

Paul is Adjunct Professor in Medical Imaging at Chalmers University of Technology. He has over 20 years’ experience in the pharmaceutical industry, where he led both imaging groups and drug safety assessment groups. A particular strength has been the evaluation of novel MRI biomarkers for use in both efficacy and safety studies. He has published over 40 peer reviewed papers and book chapters. He has also led several collaborations between industry and academia.

Day One

Tuesday May 22, 2018

11.30 | Imaging - a Holistic Way of Understanding Structure, Physiology & Function in Kidney Disease

Aliza Thompson
Medical Officer, Division of Cardiovascular & Renal Products
FDA

Day One

Tuesday May 22, 2018

09.00 | Regulatory Overview of Potential Surrogate Endpoints & Correlating Clinical Outcomes

Amrendra Ajay
Instructor of Medicine
Harvard Medical School

Day One

Tuesday May 22, 2018

13.30 | Molecular & Cellular Therapeutic Targets of Chronic Kidney Disease

Andrew King
Senior Director, Discovery Biology and Translational Science
Ardelyx

Andrew King is senior director, discovery biology and translational science at ardelyx where he oversees cellular and molecular pharmacology, in vivo pharmacology, translational and mechanistic biology and early preclinical development. Previously Andrew was principal research scientist at AbbVie where he established and led translational and mechanistic in vitro renal biology team, with the primary mission of new target identification for CKD and AKI, target validation and target advancement to late discovery.

Day Two

Wednesday May 23, 2018

14.00 | Phosphate Control in CKD & ESRD

Bert Oehlen
Principle Investigator
Angion Biomedica

Day Two

Wednesday May 23, 2018

08.30 | Aldosterone Synthase Inhibition: A New Approach to Target an Old Pathway

Bryan Fuchs
Assistant Professor of Surgery
Harvard Medical School

Day One

Tuesday May 22, 2018

16.45 | Panel Discussion: Assessing the Current & Future Landscapes for Preclinical Models

Caroline Fox
Vice President, Head, Genetics & Pharmacogenetics
Merck

Day One

Tuesday May 22, 2018

11.00 | Using Human Genetics to Drive Development - the Industry Perspective

Christina Nowack
Global Clinical Leader
Bayer

Day Two

Wednesday May 23, 2018

13.30 | Evaluating the Potential Benefits, Safety & Adverse Effects of a New Class of Mineralcorticoid Receptor Antagonists (MRA) on the Progression of DKD – FIGARO-DKD & FIDELIO-DKD

Daniel Lin
Principal Scientist, Cardiometabolic Disorders Research
Amgen

Day One

Tuesday May 22, 2018

16.45 | Panel Discussion: Assessing the Current & Future Landscapes for Preclinical Models

16.15 | Animal Models & Preclinical Drug Discovery for Chronic Kidney Disease

George Bakris
Director, Comprehensive Hypertension Centre
University of Chicago

Day Two

Wednesday May 23, 2018

16.00 | Keynote: Changing the Trajectory of CKD Diabetes: Where are we?

15.30 | Panel Discussion: Objectively Reviewing Common Pathways & Mechanisms Across Different CKD Pathologies & Evaluating Opportunities to Learn from Successful & Failed Therapeutics

Jula Inrig
Global Head Renal COE
IQVIA

Dr. Inrig is the of the Renal Center of Excellence within the Cardiovascular, Renal and Metabolic Therapeutic Science and Strategy Unit at IQVIA.   Dr. Inrig is Board certified in Nephrology and Internal Medicine from Duke University and obtained a Masters of Clinical Research from Duke University.  She has 15+ years of expertise in clinical drug development and trials spanning across academia, industry, and CRO. Global Head In her role at IQVIA, Dr. Inrig provides clinical drug development strategic support inclusive of formulation of clinical development plans, TPP, planning and designing and implementing trials, global site and country selection, clinical endpoint committees, executive steering committees, global regulatory submissions, FDA and EMA and PMDA package submissions and meetings (EOP2, EOP3, IND, Scientific advice, Type C, PSP, PIP, etc), DSMB planning and oversight, protocol writing, due diligence, global medical oversight, global feasibility, KOL relationships, steering committee/advisory boards, market analysis, and commercialization scenarios.  As the Head of the Renal Center of Excellence, Dr. Inrig also oversees the entire portfolio of Nephrology trials at IQVIA and provides scientific and strategic insight, lessons learned, scientific publications, and ongoing consultation to both internal and external teams through the lifecycle of the trials.   The portfolio of trials is inclusive of polycystic kidney disease, Alport syndrome, lupus nephritis, anemia in kidney disease, CV outcomes in kidney disease, hyperkalemia, hyperphosphatemia, renal transplantation, stem cell therapy in kidney disease, FSGS, IgA nephropathy, diabetic kidney disease, and end-stage kidney disease.

Day One

Tuesday May 22, 2018

14.00 | Optimizing Trial Planning & Implementation- the NextGen of Nephrology Trials

Heather Ascani
Director, Business Operations, Applied Systems Biology Core
University of Michigan

Day Two

Wednesday May 23, 2018

13.00 | Private Partnership Strategies for Drug Development in CKD

Jeremy Duffield
Global Head of Human Biology
Vertex Pharmaceuticals

Day One

Tuesday May 22, 2018

16.45 | Panel Discussion: Assessing the Current & Future Landscapes for Preclinical Models

08.30 | Keynote: Mapping the Future for CKD Therapeutics: Why we’ve Failed & What Needs to be Done for Success

Joseph Bonventre
Chief Renal Division
Brigham & Women’s Hospital

Day Two

Wednesday May 23, 2018

15.00 | The Continuum of Acute & Chronic Kidney Disease

Joseph Stauffer
Chief Medical Officer
Cara Therapeutics

Day Two

Wednesday May 23, 2018

09.00 | Pioneering a Novel Approach to Relieve CKD-associated Pruritus: Targeting Peripheral Kappa Receptors

Kerry Willis
Chief Scientific Officer
National Kidney Foundation

Day One

Tuesday May 22, 2018

09.30 | New Endpoints for Clinical Trials in Early Stages of CKD: Report from a Workshop Sponsored by the National Kidney Foundation, European Medicines Agency and the US Food and Drug Administration

Lijun Ma
Principal Scientist, Cardiovascular & Metabolism
Johnson & Johnson

Day One

Tuesday May 22, 2018

15.10 | An Integrin Antagonist Decreases Proteinuria & Renal Fibrosis in a Diabetic Kidney Disease Model

Mahmoud Logham-Adham
Consultant

Matthew Breyer
Former CSO Lead Generation Biotechnology Discovery research
Eli Lilly & Co

Day Two

Wednesday May 23, 2018

15.30 | Panel Discussion: Objectively Reviewing Common Pathways & Mechanisms Across Different CKD Pathologies & Evaluating Opportunities to Learn from Successful & Failed Therapeutics

Matthias Kretzler
Professor of Medicine Nephrology/ Internal Medicine & Computational Medicine & Bioinformatics
University of Michigan

Day Two

Wednesday May 23, 2018

09.30 | Precision Medicine in Kidney Disease: System Biology Driven CKD Target Identification

Shuyu Ren
Scientist II
Biogen

Day Two

Wednesday May 23, 2018

11.30 | PDGFR Signalling Promoting Organ Dysfunction by Activating Innate Immunity & PAI-1 Dependent Matrix Deposition in the Fibroblast

Tony Johnson
Chief Executive Officer
Goldfinch Bio

Day Two

Wednesday May 23, 2018

11.00 | A Novel Approach for Precision Medicine in Kidney Diseases

Venkata Sabbisetti
Instructor of Medicine
Harvard Medical School

Vishal Vaidya
Director, Global Biomarker Analytics Lead
Pfizer

Day One

Tuesday May 22, 2018

12.00 | Multi-Omics Approach to Identifying & Validating Biomarkers Representative of Population Cohorts